To further validate these findings using clinical data, we retrospectively analyzed microarray data from patients with luminal A subtype breast cancer who received long-term (16 weeks, n = 23) or short-term (4 weeks, n = 26) CDK4/6i therapy (49). The gene discussed is CDK4; the disease is breast cancer.